部份中文氢溴酸西酞普兰处方资料（仅供参考）
用法用量
口服，成人：每日 20mg～60mg，一日一次。从每日20mg开始，根据病情严重程度及患者反应可酌情增加至60mg，即每日最大剂量。增量需间隔2-3周。通常需要经过2-3周的治疗方可判定疗效。为防止复发，治疗至少持续6个月。
临床试验未见戒断症状的报道，但5-羟色胺再摄取抑制剂(SSRI)有可能出现戒断症状，因此需要经过1周的逐步减量方可停药。超过65岁的老年患者和肝功能损伤的患者，剂量减半，常用量每日10-30mg，从每日10mg开始，推荐常用剂量为每日20mg，每日最大剂量为40mg。
不良反应
本品的不良反应通常短暂且轻微。通常在服药后第一或第二周内明显，随着抑郁症状改善一般都逐渐消失。常见的不良反应有恶心、口干、头晕、头痛、嗜睡、睡眠时间缩短、多汗、流涎减少、震颤、腹泻。在国外的临床研究和上市后报告的不良反应中，与剂量相关的不良反应有疲倦、阳痿、失眠、多汗、嗜睡、喜打哈欠。
下述罕见的不良反应报道暂时认为可能与本品有关；
血管性水肿、舞蹈手足徐动症、表皮坏死、多形性红斑、肝坏死、抗抑郁药恶性综合症、胰腺炎、血清素综合症、自然流产、血小板减少、心律不齐、阴茎持续勃起症、尖端扭转性室性心动过速、戒断综合症。
在国外临床研究中还发现以下不良事件，但不一定是由本品引起的。
心血管系统：心动过速、体位性低血压、低血压、高血压、心动过缓、肢端水肿、心绞痛、期外收缩、心衰、面红、心肌梗死、脑血管意外、心肌缺血，短暂脑缺血发作、房颤、心跳骤停、束枝传导阻滞。
禁忌
对本品高度敏感者禁用。本品不能与单胺氧化酶抑制剂（MAOI’S）同时使用（见注意事项）。
注意事项
1、与单胺氧化酶抑制剂(MAOI‘s)的相互作用在同时使用5-羟色胺再摄取抑制剂(SSRI)和单胺氧化酶抑制剂(MAOI’s)的患者，曾报道发生严重或致命的反应，如体温过高、僵直、肌阵脔、重要生命体征的自主不稳定快速波动，包括精神极度兴奋所致的精神狂乱谵语或昏迷等意识改变。在近期停止使用SSRI并开始使用MAOI‘s的患者也有发生上述反应的同样报道。有些病例表现出类似精神抑制药所引起的恶性综合症。此外，有限的动物试验资料显示联合使用SSRI和MAOI’s，两者的协同作用会升高血压，并且引起行为激动。所以建议SSRI和MAOI‘s不可联合使用，或者停止服用其中任何一种药物至少14天后才可以服用另外一种药物。
2、告诫
FDA Adds More Warnings for Celexa (Citalopram)
On March 28, 2012, the FDA released a new list of dosing and use recommendations for Celexa. The new revisions state that the drug should not be given to patients with certain medical histories related to heart problems, and that the dosage of Celexa should be reduced to half of what it currently is to avoid such problems.
Celexa, or citalopram hydrobromide is an antidepressant in the same family as Zoloft and Prozac that is believed to work by increasing the amount of serotonin in the brain. The drug is in a group of medicines called selective serotonin reuptake inhibitors, or SSRIs.  Celexa has been found to change the electrical activity of the heart. Doses larger than 40mg a day could create a lengthening of the QT interval—a measure of time in the heart’s electrical system—that could lead to an abnormal and potentially fatal heart arrhythmia called Torsade de Points, or even cause death.
What Changed This Time?
The latest FDA additions to the warning labels of Celexa include a new list of recommendations. New recommendations include limiting the drug dosage to 40mg or less per day. Patients who are older than 60, have liver problems, or who are already taking inhibitors or other drugs that already lengthen the QT interval should not take more than 20mg per day. These factors increase the level of Celexa in the blood, which can increase the risk of a long QT interval and lead to Torsade de Points. Citalopram should be discontinued in patients whose QT interval measurements are consistently above 500ms.
Which Patients Are at Risk According to the New Recommendations?
Patients taking Celexa with standing heart conditions or congenital QT interval problems are shown to be the most at-risk, as well as people who have naturally low potassium and magnesium levels. For these particular patients, doctors do not recommend Celexa. Patients who are particularly at risk for these kinds of QT elongation problems must have both ECG and electrolyte monitoring while taking citalopram to avoid the risks of tachycardia, Torsade de Points, or in some cases, fatality.
What Should People Do in Response to This?
Despite these revisions, doctors tell patients not to panic. Those who are currently taking Celexa are cautioned against abruptly stopping their treatment in response to this latest medication warnings amendment. Patients who have a personal or family history of cardiac issues, and those who have questions about Celexa treatment, should consult their doctors and psychiatrists. When discussing whether Celexa treatment is right for them, it is important for patients to mention if they have had any instances of fainting.
This is not the first time that the FDA changed the dosage recommendations for Celexa; the recommendations were also altered on August 12, 2011 and March 27, 2011. In both of these revisions, the FDA reduced the recommended dosage of Celexa. These new changes will affect a significant number of Celaxa users. According to research, approximately 72 million people were using Celexa in 2011 alone, and only 6% of that total were using doses of the drug below 40mg.